{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:18:40Z","timestamp":1791685120487,"version":"4.3.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T00:00:00Z","timestamp":1532563200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004784","name":"SAS Institute","doi-asserted-by":"publisher","award":["VR942"],"award-info":[{"award-number":["VR942"]}],"id":[{"id":"10.13039\/100004784","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ebiom.2018.07.035","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T11:51:19Z","timestamp":1535025079000},"page":"67-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"special_numbering":"C","title":["Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942"],"prefix":"10.1016","volume":"35","author":[{"given":"Gary","family":"Burgess","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm","family":"Boyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Main","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frazer","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Scrimgeour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foteini","family":"Strimenopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavan","family":"Vajjah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miren","family":"Zamacona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Palframan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2018.07.035_bb0005","author":"Global Initiative for Asthma"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0010","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12931-016-0374-z","article-title":"Determinants and impact of suboptimal asthma control in Europe: the international cross-sectional and longitudinal assessment on asthma Control (LIAISON) study","volume":"17","author":"Braido","year":"2016","journal-title":"Respir Res"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0015","author":"Global asthma report"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0020","author":"European Respiratory Society"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0025","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1159\/000346910","article-title":"Adult serum cytokine concentrations and the persistence of asthma","volume":"161","author":"Kandane-Rathnayake","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0091-6749(98)70080-6","article-title":"The role of IL-13 and its receptor in allergy and inflammatory responses","volume":"102","author":"de Vries","year":"1998","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0035","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000447692","article-title":"A critical evaluation of anti-IL-13 and anti-IL-4 strategies in severe asthma","volume":"170","author":"Bagnasco","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0040","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11882-013-0373-9","article-title":"Role of interleukin-13 in asthma","volume":"13","author":"Corren","year":"2013","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0045","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jaci.2008.01.005","article-title":"Increased sputum and bronchial biopsy IL-13 expression in severe asthma","volume":"121","author":"Saha","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0050","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/cea.12729","article-title":"Sputum interleukin-13 as a biomarker for the evaluation of asthma control","volume":"46","author":"Tsilogianni","year":"2016","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0055","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/j.1365-2222.2008.02969.x","article-title":"IL-13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells","volume":"38","author":"Chibana","year":"2008","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0060","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1165\/rcmb.2006-0419OC","article-title":"Measurement of IL-13-induced iNOS-derived gas phase nitric oxide in human bronchial epithelial cells","volume":"37","author":"Suresh","year":"2007","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0065","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0070","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMoa1106469","article-title":"Lebrikizumab treatment in adults with asthma","volume":"365","author":"Corren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0075","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1365-2125.2012.04334.x","article-title":"A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics","volume":"75","author":"Hodsman","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0080","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.9120-11ST","article-title":"An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0085","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jaci.2013.03.051","article-title":"Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids","volume":"132","author":"Noonan","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0090","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1183\/09031936.00223411","article-title":"A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma","volume":"41","author":"Piper","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0095","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0100","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(18)30184-X","article-title":"Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials","volume":"6","author":"Panettieri","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0105","first-page":"1286","article-title":"Pitrakinra, a dual IL-4\/IL-13 antagonist for the potential treatment of asthma and eczema","volume":"11","author":"Antoniu","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0110","series-title":"Novel inhaled delivery of anti-IL-13 MAb (FAb fragment): Preclinical efficacy in allergic asthma","author":"Gozzard","year":"2017"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0115","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00228-012-1231-8","article-title":"TOPS: an internet-based system to prevent healthy subjects from over-volunteering for clinical trials","volume":"68","author":"Boyce","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0120","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1183\/09041950.005s1693","article-title":"Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the European Respiratory Society","volume":"16","author":"Quanjer","year":"1993","journal-title":"Eur Respir J Suppl"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0125","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.200406-710ST","article-title":"ATS\/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005","volume":"171","author":"American Thoracic Society, European Respiratory Society","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0130","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2014.01.002","article-title":"Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial","volume":"133","author":"De Boever","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0135","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/thoraxjnl-2014-206719","article-title":"Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies","volume":"70","author":"Hanania","year":"2015","journal-title":"Thorax"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0140","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(07)61600-6","article-title":"Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies","volume":"370","author":"Wenzel","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0145","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0150","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1365-3083.2006.01739.x","article-title":"High-altitude climate therapy reduces local airway inflammation and modulates lymphocyte activation","volume":"63","author":"Karagiannidis","year":"2006","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0155","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0091-6749(99)70031-X","article-title":"Allergen avoidance is associated with a fall in exhaled nitric oxide in asthmatic children","volume":"104","author":"Piacentini","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ebiom.2018.07.035_bb0160","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jaci.2007.03.039","article-title":"Reduced exhaled nitric oxide values in children with asthma after inpatient rehabilitation at high altitude","volume":"120","author":"Huss-Marp","year":"2007","journal-title":"J Allergy Clin Immunol"}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396418302792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396418302792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:48:38Z","timestamp":1762454918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396418302792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":32,"alternative-id":["S2352396418302792"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2018.07.035","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2018.07.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}